NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl Maximilian Thielmann, Klaus Griewank, Patrick Terheyden et al.|European Journal of Cancer|2021Cited by 33
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyCarl Maximilian Thielmann, Klaus Griewank, Johanna Matull et al.|European Journal of Cancer|2021Cited by 20
Characterisation and outcome of RAC1 mutated melanomaGeorg Lodde, Klaus Griewank, Philipp Jansen et al.|European Journal of Cancer|2023Cited by 14
Early versus late response to PD-1-based immunotherapy in metastatic melanomaGeorg Lodde, Selma Ugurel, Fang Zhao et al.|European Journal of Cancer|2024Cited by 9
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomasPhilipp Jansen, Klaus Griewank, Wolfgang Galetzka et al.|European Journal of Cancer|2024Cited by 4